Health Care [ 9/12 ] | Biotechnology [ 43/75 ]
NASDAQ | Common Stock
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses.
The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jan 30, 26 | -116.61 Decreased by -1.49 K% | -29.26 Decreased by -298.53% |
| Nov 14, 25 | -35.84 Increased by +88.76% | -31.08 Decreased by -15.32% |
| Aug 14, 25 | -36.68 Decreased by -646.23% | -36.68 |
| May 15, 25 | -162.40 Decreased by -5.13 K% | -105.98 Decreased by -53.24% |
| Mar 26, 25 | -7.34 Decreased by -136.64% | -5.44 Decreased by -35.00% |
| Nov 14, 24 | -318.92 Decreased by -61.46 K% | -347.48 Increased by +8.22% |
| Aug 14, 24 | -4.92 Increased by +99.89% | - |
| May 13, 24 | -3.10 Increased by +41.79% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by -100.00% | -2.66 M Decreased by -36.50% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 6.33 M Increased by +N/A% | -3.36 M Decreased by -58.22% | Decreased by -53.04% Decreased by N/A% |
| Jun 30, 25 | 22.54 M Increased by +N/A% | -2.89 M Decreased by -28.53% | Decreased by -12.83% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -3.05 M Decreased by -61.42% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 2.30 M Decreased by -57.40% | -1.95 M Increased by +2.79% | Decreased by -84.77% Decreased by -128.17% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -2.12 M Increased by +0.66% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -2.25 M Increased by +66.65% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -1.89 M Increased by +12.23% | Decreased by N/A% Decreased by N/A% |